ALK Positive joins 23andMe to Launch Lung Cancer Genetics Study to Advance Research

ATLANTA, GEORGIA, 30 JULY 2024 – ALK Positive, in collaboration with 23andMe Holding Co., a leading genetic health and biopharmaceutical company, and 20 lung cancer advocacy organizations, today announces a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people with lung cancer in order to improve detection.

ResearchKirk SmithJuly 29, 202423andMe, Research